|
Post by mnholdem on Sept 4, 2018 11:22:24 GMT -5
Additional dilution would be good luck...for short interests, that is.
|
|
|
Post by mnholdem on Sept 4, 2018 11:17:57 GMT -5
Absolutely! What a remarkable person!
Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. Rothblatt graduated from University of California, Los Angeles with a combined law and MBA degree in 1981, then began to work in Washington, D.C., first in the field of communications satellite law, and eventually in life sciences projects like the Human Genome Project.[5] She is the founder and Chairwoman of the Board of United Therapeutics. She was also the CEO of GeoStar and the creator of SiriusXM Satellite Radio.[6] She was the top earning CEO in biopharmaceutical industry in 2018.
Rothblatt is a well-known voice for medical and pharmaceutical innovation. In 1994, motivated by her daughter being diagnosed with life-threatening pulmonary hypertension,[22] Rothblatt entered the world of the life sciences by first creating the PPH Cure Foundation and later by founding a medical biotechnology company (United Therapeutics, 1996).[16] At that time she also began studying for a Ph.D. in medical ethics at the Barts and The London School of Medicine and Dentistry, Queen Mary University of London. The degree was granted in June 2001 based upon her dissertation on the conflict between private and public interests in xenotransplantation. This thesis, defended before England's leading bioethicist John Harris, was later published by Ashgate House under the title Your Life or Mine.[23] In 2013, Rothblatt was the highest-paid female CEO in America, earning $38 million.[24] Rothblatt received a total compensation of $31,581,896 in 2014. On December 5, 2017 North Carolina State University conferred her an honorary Doctor of Sciences degree.[25] On May 11, 2010 she was awarded an honorary doctorate by Ben Gurion University of the Negev in recognition of her accomplishments in satellite communications and biotechnology.[26] In April 2008, Rothblatt was elected a Member of the American Philosophical Society.[27]
As of April 2018, Rothblatt earned a compensation package worth $37.1 million from United Therapeutics. The majority of the compensation package is for stock options.[7]
Source: en.wikipedia.org/wiki/Martine_Rothblatt
|
|
|
Post by mnholdem on Sept 4, 2018 10:15:05 GMT -5
I'm wondering two things following this announcement:
1. Will TreT development continue? MannKind has yet to announce enrollment for Phase 3 trials. 2. Even though Treprostinil Technoshere (TreT) has yet to be given a marketing name, will it become Remodulin(Technosphere) or Remodulin-TS assuming that TreT uses the same treprostinil API as Remodulin?
I've been wondering why the delay in the Phase 3 trial. Now we know the reason for the delay.
|
|
|
Post by mnholdem on Sept 4, 2018 10:04:44 GMT -5
|
|
|
Post by mnholdem on Sept 4, 2018 9:29:00 GMT -5
[Clipped] I have jointed proboards after being disgusted with other boards thinking at the beginning in my naiveté that this is purely long cultists only board (cultists in the most positive meaning like being part of cult being American). Unfortunately the longer I was here the more I was convinced that this place is infected by traitors in 50 to 70%. [Clipped] "Cult" synonym: sect
At MNKD-ProBoards, we actively promote safe sects.
|
|
|
Post by mnholdem on Sept 4, 2018 9:24:49 GMT -5
Well this is one way to start the short week! Congrats to Mike and the management team for delivering on a heck of a partnership deal in a difficult situation. "Short week" - pardon the pun?
|
|
|
Post by mnholdem on Sept 4, 2018 8:32:20 GMT -5
With pre-market volume already at 500k, I think we can expect 30-50 million shares traded today...maybe more. Shorts will be scrambling for the exits and possibly create a squeeze that could propel pps higher and faster.
Good fortune all. I knew we finally hit bottom this past week/weekend when you got sour on Mike ......over 1M shares and Sports and I are the only ones awake on the left coast.....btw, remind me to payback Sports for the wake-up text at 3a lolol... Sports was already awake, I think. I was up around 2:15am Pacific Time and I recall getting her text around 3am. BTW, the UTC Agreement is great news and may help explain why Mike Castagna hasn't been out actively promoting Afrezza/MannKind, but my statements about him needing to become much more visible as CEO haven't changed with this terrific announcement. Perhaps now he'll have more time to get out there on more than digital media, unless he's tied down with additional negotiations for global Afrezza partners.
I think that shareholders are all still waiting for a PR about a China deal, since Mike stated at a conference earlier this year that MannKind would be filed and actively seeking market approval in countries that represent +50% of the worldwide diabetes population. Brazil and India combined falls short of that stated target.
Regardless, congratulations to CEO Castagna on the newest deal.
|
|
|
Post by mnholdem on Sept 4, 2018 7:08:48 GMT -5
I was chatting with someone this morning about what the added impact of a China announcement could do to share price.
|
|
|
Post by mnholdem on Sept 4, 2018 7:06:49 GMT -5
The Sanofi deal was bigger than this and that had us up to $10-11. But now we have roughly 70% fewer shares, anyone care to take a guess? $8-9 short term... maybe... with some decent follow up info from the upcoming conference calls. Sanofi was bigger due to fda approval. The part I like best is the opportunity to replay p3 trial outcomes, any achom news, and fda approval of Inhaled TrepT. Been here done this,,, right ? 😎 Perhaps what you say is true, rockstarrick, but this new Agreement validates Technosphere technology and gives UTC the right to develop additional API at $10 million upfront plus double-digit royalties for each API. Long-term investors, like you, know that TS-API possibilities are endless.
What if UTC decides to develop a TS-API for migraines? The market would eclipse insulin.
This Agreement is exciting news and, as another PB member pointed out to me earlier this morning, it's very good news that the collaboration to develop additional TS-APIs is with a big pharmaceutical company rather than a venture capitalist.
|
|
|
Post by mnholdem on Sept 4, 2018 6:55:37 GMT -5
|
|
|
Post by mnholdem on Sept 4, 2018 6:54:51 GMT -5
|
|
|
Post by mnholdem on Sept 4, 2018 6:48:09 GMT -5
With pre-market volume already at 500k, I think we can expect 30-50 million shares traded today...maybe more. Shorts will be scrambling for the exits and possibly create a squeeze that could propel pps higher and faster.
Good fortune all.
|
|
|
Post by mnholdem on Sept 3, 2018 16:21:35 GMT -5
Cipla does serve more countries than just India, though: “Cipla has a wide presence internationally, covering South-East Asia, Middle-East, Latin America, Africa, Australia, New Zealand and Russia-CIS. The company offers a diverse range of more than 1000 products in over 100 countries.” Source: www.cipla.com/en/our-businesses/geographies/international.html
|
|
|
Post by mnholdem on Sept 3, 2018 16:16:08 GMT -5
Even though these were recent articles (2 were published in September 2018) I dug a little deeper and learned that the International Diabetes and Endocrine Congress (IDEC) in Karachi, Pakistan was held August 19-22, 2016.
These articles do not mention being reprints but they do state the comments were made at that conference.
So, unfortunately, I now think this may be old news. My apologies if it is. Since that time, I think MannKind CEO mentioned, in effect, that he was scuttling deals with individual countries in preference to negotiating a deal with a regional player.
Cipla may be the exception to this because of the sheer size of the diabetes market in India.
|
|
|
Post by mnholdem on Sept 3, 2018 13:56:58 GMT -5
|
|